Halo-Bio RNAi Therapeutics
Halo Bio is a biotechnology company focused on developing innovative RNAi-based biopharmaceuticals. Their platform integrates RNA Core, RNA Shells, and Particle Shells to create targeted, bioavailable nanoparticle medicines for treating human diseases, including viral infections like SARS-2. They aim to overcome delivery challenges in RNA therapeutics and develop rapid-response treatments for viral outbreaks.
Industries
Nr. of Employees
small (1-50)
Halo-Bio RNAi Therapeutics
Washington, District of Columbia, United States, North America
Patents
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US-10731157-B2
View DetailsPolynucleotides for multivalent RNA interference, compositions and methods of use thereof
US-9200276-B2
View Details
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US-10731157-B2
View DetailsPolynucleotides for multivalent RNA interference, compositions and methods of use thereof
US-9200276-B2
View DetailsProducts
RNA nanoparticle therapeutic platform (self-assembling core + programmable shell)
A platform architecture combining a self-assembling single-stranded RNA core that functions as the active ingredient with a programmable aptamer-driven protein shell to enable tissue targeting and intracellular delivery.
Antiviral replicating RNA therapeutic candidate (respiratory delivery)
Design-stage replicating subviral RNA constructs intended to suppress viral mRNA expression in infected cells; candidates are being prepared for production and preclinical testing and considered for intrapulmonary or nasal delivery.
RNA nanoparticle therapeutic platform (self-assembling core + programmable shell)
A platform architecture combining a self-assembling single-stranded RNA core that functions as the active ingredient with a programmable aptamer-driven protein shell to enable tissue targeting and intracellular delivery.
Antiviral replicating RNA therapeutic candidate (respiratory delivery)
Design-stage replicating subviral RNA constructs intended to suppress viral mRNA expression in infected cells; candidates are being prepared for production and preclinical testing and considered for intrapulmonary or nasal delivery.
Services
Computational design and sequence engineering of multivalent RNA triggers and self-assembling RNA cores for target gene suppression and candidate generation.
Production and formulation of RNA nanoparticle candidates using scalable cell-free systems, including plant cell-free platforms, and formulation into VLP or lipoplex vehicles.
Licensing and partnership arrangements to access RNA sequences, peptide/protein surfaces, or co-develop pipeline candidates.
Computational design and sequence engineering of multivalent RNA triggers and self-assembling RNA cores for target gene suppression and candidate generation.
Production and formulation of RNA nanoparticle candidates using scalable cell-free systems, including plant cell-free platforms, and formulation into VLP or lipoplex vehicles.
Licensing and partnership arrangements to access RNA sequences, peptide/protein surfaces, or co-develop pipeline candidates.
Expertise Areas
- RNAi therapeutic design
- Self-assembling RNA nanoparticle engineering
- Nanoparticle surface engineering with aptamers
- Antiviral RNA therapeutics
Key Technologies
- RNA interference (RNAi)
- Multivalent RNA triggers
- Self-assembling single-stranded RNA nanoparticles
- Aptamer-directed protein surfaces